INSM · Insmed Inc
Price
Snapshot
50 fields · last close| Market Cap | $21.02B |
| P/E | — |
| Float | 215.4M |
| Beta | 0.83 |
| Volatility | 20.9% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 57.6 |
| Price | 96.33 |
| Change | +0.06% |
| Prev Close | 96.27 |
| Open | 98.70 |
| Day Low | 96.05 |
| Day High | 99.00 |
| Avg Vol | 3 |
| Avg $ Vol | $311.0M |
| 52W High | 212.75 |
| 52W Low | 90.39 |
| 52W Pos | 4.9% |
| From High | −54.72% |
| From Low | +6.57% |
| Max DD 1Y | −56.54% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −11.10% |
| SMA 50 | −18.96% |
| SMA 200 | −25.38% |
| RSI (14) | 29.1 |
| Vol 30D | 38.8% |
| Vol 90D | 62.8% |
| 1Y Range | 90–213 |
| Daily bars | 536 |
| Perf Week | −4.30% |
| Perf Month | −22.35% |
| Perf Quarter | −10.04% |
| Perf Half Y | −33.37% |
| Perf Year | −41.13% |
| Perf YTD | −45.61% |
| Prev Day | +0.06% |
| Clavix | C |
| Debt / Eq | 0.74 |
| Curr Ratio | 3.83 |
| Int Cover | -34.1× |
| FCF Margin | — |
| Rev Growth | +66.7% |
| Profit | Unprofitable |
| Leverage | Moderate |
| Sector rank | 29 / 35 |
Clavix risk grade
regraded every trading dayINSM grades C, 57.6 of 100. Steadiest on News Sentiment (57), most exposed on Price Stability (39, fragile). 0 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 29 of 35 in Biotechnology by Clavix score.
How rough the ride is
| INSM | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.83 | 0.51 |
| Volatilityannualized | 20.9% | 14.6% |
| Max drawdown, past yearworst peak-to-trough fall | −56.5% | — |
| Typical daily movemedian absolute daily change | 1.59% | — |
| Days beyond ±3%of the last 252 sessions | 53 (21%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| INSM | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.83 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| INSM | |
|---|---|
| 1 week | −4.3% |
| 1 month | −22.4% |
| Year to date | −45.6% |
| 1 year | −41.1% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| INSM | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 6 Aug |
| Average score0 most bearish, 100 most bullish | 65 |
| Bullish · bearisharticles above 60 · below 40 | 21 · 2 |
| Directionarticles whose tone is improving vs worsening | 21 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| INSM | |
|---|---|
| Revenue growthyear over year | +66.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openInsmed announced the commercial launch in Japan of BRINSUPRI Tablets 25 mg (brensocatib hydrate), an oral once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children aged 12 and older.
An analysis examines whether Insmed's TPIP prodrug (an inactive form that converts to an active drug in the body) has a clear patent path around Tyvaso, a competing drug from United Therapeutics. Filings show Insmed's TPIP patent estate runs through 2034, but they don't confirm Insmed can operate without infringing United Therapeutics' patents.
Several Wall Street analysts updated their coverage of Insmed (INSM) on October 12, 2026: Bank of America reaffirmed a 'buy' rating with a $207 price target, while Wolfe Research downgraded the stock from 'outperform' to 'peer perform.' The rest of the article body was cut off and additional analyst updates were not visible.
Insmed will showcase its global Phase 3 PALM Clinical Development Program for treprostinil palmitil inhalation powder (TPIP) at the CHEST 2026 medical conference. The program consists of four parallel-running pivotal Phase 3 studies (PALM-PAH, PALM-ILD, PALM-PPF, and PALM-IPF) across four progressive pulmonary diseases.
HC Wainwright analyst A. Fein raised their Q3 2026 earnings-per-share estimate for Insmed to a projected loss of $0.13 per share, up from a prior forecast. The article was cut off before giving the earlier estimate or any rating details.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| UTHR | United Therapeutics Corp | B | $22.87B | 17.44 | 0.50 | Compare |
| INCY | Incyte Corp | B+ | $22.92B | 14.21 | 0.79 | Compare |
| EXEL | Exelixis Inc | B+ | $15.42B | 17.92 | 0.44 | Compare |
| ALNY | Alnylam Pharmaceuticals Inc | C+ | $31.02B | 38.39 | 0.37 | Compare |
| ASND | Ascendis Pharma A/S | B+ | $14.05B | 16.85 | 0.39 | Compare |
| HALO | Halozyme Therapeutics Inc | B | $13.83B | 33.44 | 0.93 | Compare |
| NBIX | Neurocrine Biosciences Inc | B+ | $13.79B | 19.55 | 0.34 | Compare |
| BBIO | BridgeBio Pharma Inc | B | $12.98B | — | 0.95 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.